Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2021

View Archived Issues

HER2 CAR-NK cells show preclinical antitumor activity without off-target cytotoxicity

TGF-beta-mediated mTOR inhibition preserves cellular metabolism of precursors of exhausted T cells

New prosthetic valvular graft infection model shows benefit of adjunctive fibrinolytic treatment

Model of steroid-resistant neutrophilic asthma developed to test treatments

GFAP a biomarker in frontotemporal lobar degeneration and primary psychiatric disorders

TYK Medicines divulges new Ret inhibitors

Wigen Biomedicine Technology presents KRAS mutant inhibitors

FDA accepts IND application for phase IIa study of Quilience as treatment of narcolepsy

UCB discloses new FCER1A mutant inhibitors

FDA clears IND for phase I trial of SYSA-1801 in advanced pancreatic cancer

Phase I trial investigates SHJ-002 for myopia in pediatric subjects

ABBV-CLS-7262 studied in phase I for ALS

BIX-119 leads to improved clinical benefit through blocking both IL-17 and IL-22

Scioto opens phase I study of SB-121 in participants with autistic disorder

New neonatal murine model of Listeria monocytogenes meningitis developed

Clarity recruits patients with prostate cancer to evaluate PET imaging with [64Cu]SAR-bisPSMA

Discovery of novel selective Axl inhibitor with antitumor activity in vivo

Phase II/III trial studies SHR-1701 with BP-102 and XELOX in first-line metastatic colorectal cancer

U.S. phase II trial explores use of Velexbru in primary central nervous system lymphoma

CytoDyn reports preliminary data on leronlimab in metastatic TNBC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...